GlassScriptPhysician profile
Pedro A Blandon
NPI 1275531469
$8,358.54
in general payments reported to CMS, 2019-2025
35 companies · $1,436 in 2025
The $1,436 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.50 · 2020: $150 · 2021: $650 · 2022: $1,156 · 2023: $1,186 · 2024: $3,686 · 2025: $1,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,349 · Consulting Fee: $2,850 · Travel and Lodging: $83.10 · Education: $26.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,348.59 |
| Consulting Fee | $2,850.00 |
| Travel and Lodging | $83.10 |
| Education | $26.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $3,064.87 | 2024-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $695.56 | 2021-2025 | |
| Ardelyx, INC. | $421.16 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Amgen INC. | $384.65 | 2019-2025 | Krystexxa, Evenity |
| Otsuka America Pharmaceutical, INC. | $356.10 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $354.26 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $288.07 | 2021-2023 | Krystexxa |
| Novo Nordisk INC | $272.84 | 2022-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.41 | 2024-2025 | Jardiance |
| Abbott Laboratories | $249.53 | 2021-2023 | Freestyle Libre 3 |
| Travere Therapeutics, INC. | $233.53 | 2023-2025 | |
| Nxstage Medical, INC. | $201.75 | 2020-2024 | |
| Genzyme Corporation | $184.53 | 2019-2025 | |
| Inspire Medical Systems, INC. | $165.24 | 2022 | |
| Scpharmaceuticals INC. | $163.31 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $160.18 | 2025 | Ellipsys Vascular Access System |
| Novartis Pharmaceuticals Corporation | $126.91 | 2021-2025 | |
| Vifor Pharma, INC. | $126.53 | 2020-2024 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $93.68 | 2022-2023 | Benlysta, Shingrix |
| Allergan, INC. | $76.35 | 2020 | |
| Abbvie INC. | $67.76 | 2021 | |
| Astellas Pharma US INC | $63.78 | 2023 | Veozah, Myrbetriq |
| Akebia Therapeutics INC | $48.83 | 2022-2024 | Auryxia |
| Ani Pharmaceuticals, INC. | $42.71 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $36.08 | 2022 | |
| Amarin Pharma, INC. | $31.82 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.59 | 2020 | |
| Aurinia Pharma U.S., INC. | $30.11 | 2022 | |
| Apellis Pharmaceuticals, INC. | $23.12 | 2025 | |
| Fresenius USA Marketing, INC. | $23.03 | 2023 | Velphoro, Korsuva |
| Beta Bionics, INC. | $19.36 | 2024 | Ilet Bionic Pancreas |
| Alexion Pharmaceuticals, INC. | $19.02 | 2022 | |
| Boston Scientific Corporation | $16.47 | 2023 | Solyx Sis System |
| Outset Medical INC | $10.62 | 2023 | |
| Biomerieux INC | $5.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Blandon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.